Observational studyFrontiers in endocrinology2025
Obesity results in lower integrin expression in women with polycystic ovarian syndrome during the window of implantation.
Observational study in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04175002 (Endometrial Heparin-binding Epidermal Growth Factor Expression in Implantation Window of Obese Women With Polycystic Ovarian Syndrome), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Endometrial Heparin-binding Epidermal Growth Factor Expression in Implantation Window of Obese Women With Polycystic Ovarian Syndrome(PCOS)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that is characterized by hormonal imbalances and ovarian dysfunction. Obesity is also a prevalent issue that has been linked to the development of PCOS. The present study aimed to investigate the gene expression of αvβ3 integrin, mucin-1, and E-cadherin in obese and non-obese women with and without PCOS. Methods: This prospective study was undertaken at the Advanced Reproductive Centre at Hospital Canselor Tuanku Muhriz (Universiti Kebangsaan Malaysia) from January 2019 to June 2021. A total of 40 women were recruited for the study and divided equally (n = 10) into four groups, namely, i) control with normal body weight, ii) control obese, iii) PCOS with normal body weight, and iv) PCOS obese. An endometrial tissue sample was collected after 10 days of daily oral micronized progesterone (Utrogestan 200 mg) in the PCOS group. In the fertile or control group, midsecretory phase endometrial biopsy was performed following 7 days post-ovulation. Then, total RNA was isolated from the endometrial tissue. Gene expression was analyzed using RT-qPCR. Results: The results showed that the mRNA expression of αVβ3-integrin was significantly decreased in the PCOS obesity group compared to the PCOS normal body weight group and the control normal body weight group. No significant differences were observed in mucin-1 and E-cadherin expression between the groups. Conclusion: αvβ3 integrin plays an important role in the development of the window of implantation in obese PCOS individuals. Further research is needed to confirm these results and to identify the potential mechanisms underlying this association. Clinical trial registration: ClinicalTrial.gov, identifier NCT04175002.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.